An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate.

Trial Profile

An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2013

At a glance

  • Drugs Motesanib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center).
    • 25 Aug 2009 Additional trial locations added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Actual end date (1 Jun 2008) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top